¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Alpha Lipoic Acid Oral"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • acid fast
    Ç×»ê(¼º)(ù÷ß«àõ)ÀÇ.
  • acid fast bacillus (AFB)
    Ç×»ê±Õ, Ç׻긷´ë±Õ
  • acid fast bacterium
    Ç×»ê(¼º) ¼¼±Õ.
  • acid fast bacterium
    Ç×»ê(¼º) ¼¼±Õ.
  • acid fast organism
    Ç×»ê±Õ
  • acid fast stain
    Ç×»ê(¼º) ¿°»ö(¡­æøßä).
  • acid fastness
    Ç׻꼺
  • acid food
    »ê¼º½Äǰ.
  • acid forming
    »ê¹ß»ý(ß«Û¡ßæ)ÀÇ.
  • acid free diet
    ¹«»ê½ÄÀÌ.
  • acid hematin method
    »êÇ츶ƾ¹ý(¡­Ûö).
  • acid intoxication
    »êÁßµ¶(Áõ)(ß«ñéÔ¸ñø).
  • acid lipase deficiency
    »ê¼º ¸®ÆÄÁ¦ °áÇÌÁõ(ß«àõ¡­ÌÀù¹ñø)
  • acid mucopolysaccharide(s)
    »ê¼ºÁ¡´Ù´çÁú(ïÄÒýÓØòõ)
  • acid perfusion
    »ê°ü·ù(߫δêü), »êȯ·ù.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • pteroylglutamic acid
    Å×·ÎÀϱ۷玻ê(ß«)
  • PTH-amino acid
    PTH ¾Æ¹Ì³ë»ê(ß«)
  • pyroglutamic acid
    ÇǷα۷玻ê(ß«)
  • pyruvic acid
    ÆÄÀÌ·çºê»ê(ß«)
  • radical amino acid replacement
    ¶óµðÄ® ¾Æ¹Ì³ë»ê ġȯ(öÇüµ)
  • rare amino acid
    Èñ±Í(ýüÏþ) ¾Æ¹Ì³ë»ê
  • reductive carboxylic acid cycle
    ȯ¿ø¼º(ü½êªàõ) Ä«¸£º¹½Ç»ê(ß«) ȸ·Î(üÞÖØ)
  • reductive tricarboxylic acid cycle
    ȯ¿ø¼º(ü½êªàõ) Æ®¸®Ä«¸£º¹½Ç»ê(ß«) ȸ·Î(üÞÖØ)
  • resin acid
    ¼öÁö»ê(â§ò·ß«)
  • ribonucleic acid
    ¶óÀ̺¸ÇÙ»ê(ú·ß«)
  • ribose nucleic acid
    ¶óÀ̺¸½º ÇÙ»ê(ú·ß«)
  • ribothymidylic acid
    ¶óÀ̺¸Å¸À̵̹ô»ê(ß«)
  • saccharic acid
    »çÄ«¸°»ê(ß«)
  • saturated fatty acid
    Æ÷È­ Áö¹æ»ê(øéûùò·Û¸ß«)
  • secondary bile acid
    ÀÌÂ÷ ´ãÁó»ê(ì£ó­ÓÅñðß«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
T(O) oral temperature
TOPV trivalent oral poliovaccine
PAS   1) Periodic Acid-Schiff Stain
  2) Para-Amino-Salicyclic Acid
 &nbs...
AHA acetohydroxamic acid; acquired hemolytic anemia; acute hemolytic anemia; American Heart Association;...
AP accessory pathway; accounts payable; acid phosphatase; acinar parenchyma; action potential; active p...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
alpha-BuTx Alpha-Bungarotoxin
alpha-GAL Alpha-Galactosidase
alpha-LA Alpha-Lactalbumin
alpha-MSH Alpha-Melanocyte stimulating hormone
alpha-MPT alpha-methyl-L-p-tyrosine
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • xanthourenic acid
    ÀÜÅõ·»»ê
    4,8-dihydroxyquinaldic acid. L-try
  • xylic acid
    ÀÚÀϸ°[Å©½Ç]»ê
    °áÁ¤»ê.
  • zinc oxide-ethoxybenzoic acid cement
    EBA ½Ã¸àÆ®
    »êÈ­ ¾Æ¿¬ À¯Áö³î ½Ã¸àÆ®ÀÇ ¾×Áß¿¡¼­ À¯Áö³îÀÇ ´ëºÎºÐÀ» EBA·Î ´ëüÇÑ Ä¡°ú¿ë ½Ã¸àÆ®.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
d(-)-alpha-aminobenzylpenicillin <drug> Penicillin derivative with broad spectrum activity, ampicillin resistance is often used as a marker for plasmid transfer in genetic engineering (for example pBR322 is ampicillin resistant).
(13 Nov 1997)
deficiency, alpha-1 antitrypsin An inherited disease with little or no production of an important protein, alpha-1 antitrypsin. The lack of this protein leads to damage of various organs, mainly the lung and liver. The disease may become apparent at a very early age or in adulthood, as shortness of breath or liver-related symptoms (jaundice, fatigue, fluid in the abdomen, mental changes, or gastrointestinal bleeding). There are several options for treatment of the lung disease, including replacement of the missing protein. Treatment of the liver disease is a well-timed liver transplant
(12 Dec 1998)
delta-(alpha-aminoadipyl)cysteinylvalinedisulfide reductase <enzyme> Broad range disulfide reductase from streptomyces clavuligerus; requires NADPH; involved in the production of beta-lactam antibiotic such as penicillins and cephalosporins
Registry number: EC 1.6.4.-
Synonym: bis-acv reductase, delta-(-l-alpha-aminoadipyl)-l-cysteinyl-d-valine disulfide reductase, acv disulfide reductase
(26 Jun 1999)
dextrin 6-alpha-d-glucosidase <enzyme> Catalyses endohydrolysis of 1,6-alpha-d-glucoside linkages at points of branching in chains of 1,4-linked alpha-d-glucose residues
Registry number: EC 3.2.1.33
(26 Jun 1999)
diadenosine 5,5'''-P(1),P(4)-tetraphosphate alpha,beta-phosphorylase <enzyme> Ap4a + inorganic po4 forms ATP + ADP
Registry number: EC 2.7.7.53
Synonym: ap4a phosphorylase, ATP adenylyltransferase
(26 Jun 1999)
dihydrostreptomycin-6-phosphate 3' alpha-kinase <enzyme> Catalyses the phosphorylation of dihydrostreptomycin 6-phosphate in the 3'-position in the presence of ATP
Registry number: EC 2.7.1.88
Synonym: dihydrostreptomycin-6-p 3' alpha-kinase
(26 Jun 1999)
dolichyl-phosphate alpha-N-acetylglucosaminyltransferase <enzyme> Combined with EC 2.4.1.141 forms chitobiosylpyrophosphoryldolichol synthase
Registry number: EC 2.4.1.153
Synonym: dpagtransferase
(26 Jun 1999)
dolichyl-phosphate-mannose-glycolipid alpha-mannosyltransferase <enzyme> Catalyses the transfer of mannose from dolichyl-p-mannose to the man(5)(glcnac)2-pp-dolichol acceptor glycolipid
Registry number: EC 2.4.1.130
Synonym: dolichyl-p-mannose-dolichyl-pp-heptasaccharide alpha-mannosyltransferase, dolichyl-p-mannose-man(5)(glcnac)2-pp-dolichol mannosyltransferase, dpm-g-mannosyltransferase
(26 Jun 1999)
D-selenocystine alpha, beta-lyase <enzyme> From clostridium sticklandii; pyridoxal-p enzyme; mw 74kda; decomposes d-selenocystine into pyruvate, nh3 and elemental selenium; d-cystine, d-lanthionine, meso-lanthionine and d-cysteine can also serve as substrates; d-selenocysteine, d-serine, dl-selenohomocystine and l-amino acids are inert
Registry number: EC 4.99.-
Synonym: dsc-ab-lyase
(26 Jun 1999)
I kappa B alpha-associated protein kinase <enzyme> Isolated from human monocytic cell line; phosphorylates ser(293), ser(288), and thr(291) of ikappabalpha
Registry number: EC 2.7.10.-
Synonym: ikappabalpha-associated protein kinase, ikappab-alpha-associated protein kinase, ikappabalpha kinase
(26 Jun 1999)
immunoglobulins, alpha-chain Heavy chains found in the fab and fc fragments of IgA and having a molecular weight of approximately 58 kD. They contain about 470 amino acid residues arranged in four domains and an oligosaccharide component bound covalently to the fc fragment.
(12 Dec 1998)
indolyl-3-alkane-alpha-hydroxylase <enzyme> Indoyl-3-alkane-alpha-hydroxylase; haemprotein which needs no cofactor
Registry number: EC 1.13.99.-
Synonym: tryptophan side chain oxidase
(26 Jun 1999)
inositol 1-alpha-galactosyltransferase <enzyme> Catalyses conversion of udpgalactose plus myo-inositol to galactinol plus udp
Registry number: EC 2.4.1.123
Synonym: galactinol synthase
(26 Jun 1999)
inter-alpha-inhibitor <chemical> Inhibits bovine trypsin and chymotrypsin; complex formed with chymotrypsin less stable; alpha-glycoprotein; shap - serum-derived hyaluronan associated protein
Pharmacological action: serine proteinase inhibitors, trypsin inhibitors
Chemical name: trypsin inhibitor, inter-alpha-
Synonym: inter-alpha-trypsin inhibitor, protein pi, inter-alpha-trypsin inhibitor, heavy chain, shap protein
(05 Dec 1998)
interferon-alpha <cytokine> One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products.
It is the major interferon produced by virus-induced leukocyte cultures and, in addition to its pronounced antiviral activity, causes activation of NK cells. It is used experimentally in the treatment of hairy-cell leukaemia.
A number of different subtypes exist that are elaborated by leukocytes in response to viral infection or stimulation with double-stranded RNA; IFN-alpha-2A and -2B are protein products made by recombinant DNA techniques and are used as antineoplastic agents.
See: interferon-alpha 2a, interferon-alpha 2b
Synonym: leukocyte interferon.
Pharmacological action: antineoplastic agent, antiviral agent.
(20 Sep 2002)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á